Literature DB >> 3297205

Marrow transplantation for children with acute lymphoblastic leukemia in second remission.

J E Sanders, E D Thomas, C D Buckner, K Doney.   

Abstract

Fifty-seven children between the ages of 3 and 17 years with acute lymphoblastic leukemia (ALL) in chemotherapy-induced second bone marrow remission were given cyclophosphamide, total body irradiation, and bone marrow transplants from HLA-matched donors. Sixteen died of transplant-related complications. Eighteen relapsed between 56 and 833 days after transplantation, and 16 died of leukemia. Two survive in remission off treatment following chemotherapy. Twenty-three survive in continuous remission from 1.4 to 10.4 years after transplantation and the actuarial analysis shows disease-free survival of 40% with a plateau extending from 2.5 to 10.4 years.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3297205

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  5 in total

Review 1.  Bone marrow transplantation for leukaemia.

Authors:  J M Chessells
Journal:  Arch Dis Child       Date:  1988-08       Impact factor: 3.791

2.  Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group.

Authors:  ZoAnn E Dreyer; Patricia A Dinndorf; Bruce Camitta; Harland Sather; Mei K La; Meenakshi Devidas; Joanne M Hilden; Nyla A Heerema; Jean E Sanders; Ron McGlennen; Cheryl L Willman; Andrew J Carroll; Fred Behm; Franklin O Smith; William G Woods; Kamar Godder; Gregory H Reaman
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

Review 3.  Hematopoietic stem cell transplantation for leukemia.

Authors:  Alan S Wayne; Kristin Baird; R Maarten Egeler
Journal:  Pediatr Clin North Am       Date:  2010-02       Impact factor: 3.278

4.  Chemotherapy for bone marrow relapse of childhood acute lymphoblastic leukemia.

Authors:  G Henze; R Fengler; R Hartmann; R Dopfer; U Göbel; N Graf; H Jürgens; D Niethammer; J Ritter; G Schellong
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Improvement of induction remission rate by modifying the dose of idarubicin for relapsed childhood acute lymphoblastic leukemia.

Authors:  Jong Hyung Yoon; Jeong Ah Park; Eun Kyung Kim; Hyoung Jin Kang; Hee Young Shin; Hyo Seop Ahn
Journal:  J Korean Med Sci       Date:  2009-04-20       Impact factor: 2.153

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.